These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20569707)

  • 21. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
    Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between cigarette smoking and clinical benefit of clopidogrel.
    Desai NR; Mega JL; Jiang S; Cannon CP; Sabatine MS
    J Am Coll Cardiol; 2009 Apr; 53(15):1273-8. PubMed ID: 19358940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
    N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Double Loading Regimen of Clopidogrel on Final Angiographic Results, Incidence of Upper Gastrointestinal Bleeding and Clinical Outcomes in Patients with STEMI Undergoing Primary Coronary Intervention.
    Tong MS; Sung PH; Liu CF; Chen KH; Chung SY; Chua S; Chen CJ; Lee WC; Chai HT; Yip HK; Chang HW
    Int Heart J; 2017 Oct; 58(5):686-694. PubMed ID: 28966310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
    Pride YB; Appelbaum E; Lord EE; Sloan S; Cannon CP; Sabatine MS; Gibson CM;
    Am J Cardiol; 2009 Aug; 104(4):475-9. PubMed ID: 19660597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study.
    Patti G; Bárczi G; Orlic D; Mangiacapra F; Colonna G; Pasceri V; Barbato E; Merkely B; Edes I; Ostojic M; Wijns W; Di Sciascio G
    J Am Coll Cardiol; 2011 Oct; 58(15):1592-9. PubMed ID: 21958886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
    McLean DS; Sabatine MS; Guo W; McCabe CH; Cannon CP
    J Thromb Thrombolysis; 2007 Oct; 24(2):85-91. PubMed ID: 17323134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
    Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
    Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Fox KA; Granger CB; Jolly S; Rupprecht HJ; Widimsky P; Yusuf S;
    Am Heart J; 2008 Dec; 156(6):1080-1088.e1. PubMed ID: 19033002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention.
    Larson DM; Duval S; Sharkey SS; Solie C; Tschautscher C; Lips DL; Burke MN; Steinhubl S; Henry TD
    Am Heart J; 2010 Jul; 160(1):202-7. PubMed ID: 20598993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
    Dangas G; Mehran R; Guagliumi G; Caixeta A; Witzenbichler B; Aoki J; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Rabbani LE; Parise H; Stone GW;
    J Am Coll Cardiol; 2009 Oct; 54(15):1438-46. PubMed ID: 19796737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
    Gibler KB; Huskamp HA; Sabatine MS; Murphy SA; Cohen DJ; Cannon CP
    Crit Pathw Cardiol; 2010 Mar; 9(1):14-8. PubMed ID: 20215905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.